Related Experiment Video

Updated: Jul 5, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Clinical development of mTOR inhibitors: a focus on lymphoma

Sonali M Smith1

  • 1The University of Chicago Hospitals, Chicago, IL 60637, USA. msmith@medicine.bsd.uchicago.edu

Reviews on Recent Clinical Trials
|May 14, 2008
PubMed

Insights

Mammalian target of rapamycin (mTOR) kinase inhibitors show promise for treating lymphoma. Early clinical trials indicate these drugs are well-tolerated and demonstrate encouraging activity in patients with lymphoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, proliferation, and translation.
  • mTOR is a downstream effector of the PI3K/Akt pathway, implicated in oncogenesis.
  • Preclinical studies demonstrate that inhibiting mTOR can lead to lymphoma regression.

Purpose of the Study:

  • To review the rationale for investigating mTOR inhibitors in lymphoma treatment.
  • To analyze Phase 1 clinical trials that informed the dosing and scheduling of mTOR inhibitors.
  • To summarize current clinical outcomes of mTOR inhibitors in lymphoma patients.

Main Methods:

  • Review of preclinical data supporting mTOR inhibition in lymphoma.
  • Analysis of Phase 1 clinical trial results for mTOR inhibitors.
  • Summary of published clinical data on mTOR inhibitors in lymphoma.

Main Results:

  • mTOR inhibitors are emerging as well-tolerated agents in lymphoma treatment.
  • Early clinical data show encouraging preliminary activity of mTOR inhibitors.
  • Rapamycin, temsirolimus, everolimus, and AP23573 are key mTOR inhibitors in development.

Conclusions:

  • The rationale for using mTOR inhibitors in lymphoma is supported by preclinical and early clinical data.
  • mTOR inhibitors represent a promising therapeutic strategy for lymphoma.
  • Ongoing research and clinical trials are crucial for further evaluating these agents.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...